Email this article Stereotactic body radiation therapy for clinically localized prostate cancer
- Authors: Vorobyov N.A.1,2,3, Martynova N.I.1, Mikhailov A.V.1, Gutsalo Y.V.1, Kubasov A.V.1
-
Affiliations:
- Medical and Diagnostic Center of the S. Berezin International Institute of Biological Systems
- Saint Petersburg State University
- I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia
- Issue: Vol 14, No 2 (2018)
- Pages: 122-129
- Section: DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. PROSTATE CANCER
- Published: 30.06.2018
- URL: https://oncourology.abvpress.ru/oncur/article/view/821
- DOI: https://doi.org/10.17650/1726-9776-2018-14-2-122-129
- ID: 821
Cite item
Full Text
Abstract
Background. In the last decade, we observed a significant increase in the number of patients undergoing radiotherapy for prostate cancer (PC). It became possible with the development of new equipment that can significantly increase radiation efficiency and reduce the frequency and severity of side effects. Active investigation of new fractionation regimens led to the development of stereotactic radiotherapy (StR) technique. In this article, we describe our own experience of using StR in patients with localized PC.
Material and methods. The study included 48 patients treated with CyberKnife robotic radiosurgery system. The patients received a total dose of 36.25 Gy delivered in 5 fractions.
Results. At a median follow-up of 24 months, the estimated four-year prostate-specific antigen (PSA) relapse-free survival rate was 95.8 %. The median PSA nadir was 0.48 ng/mL. We observed no grade III–IV side effects (either early or late).
Conclusion. Our results suggest that the use of StR allows achieving good biochemical control comparable to that achieved by other methods and demonstrates comparable and sometimes even lower toxicity.
About the authors
N. A. Vorobyov
Medical and Diagnostic Center of the S. Berezin International Institute of Biological Systems;Saint Petersburg State University;
I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia
Author for correspondence.
Email: vorobyovofficial@gmail.com
ORCID iD: 0000-0002-6998-5771
43 Karla Marksa St., Pesochniy, Saint Petersburg 197758 Russian Federation
N. I. Martynova
Medical and Diagnostic Center of the S. Berezin International Institute of Biological Systems
Email: martynova@ldc.ru
ORCID iD: 0000-0002-1679-5173
43 Karla Marksa St., Pesochniy, Saint Petersburg 197758 Russian Federation
A. V. Mikhailov
Medical and Diagnostic Center of the S. Berezin International Institute of Biological Systems
Email: mikhaylov@ldc.ru
ORCID iD: 0000-0002-5240-7203
43 Karla Marksa St., Pesochniy, Saint Petersburg 197758 Russian Federation
Yu. V. Gutsalo
Medical and Diagnostic Center of the S. Berezin International Institute of Biological Systems
Email: gutsalo@ldc.ru
ORCID iD: 0000-0001-8387-937X
43 Karla Marksa St., Pesochniy, Saint Petersburg 197758
A. V. Kubasov
Medical and Diagnostic Center of the S. Berezin International Institute of Biological Systems
Email: antonkubasov@ldc.ru
43 Karla Marksa St., Pesochniy, Saint Petersburg 197758 Russian Federation
References
Supplementary files
